These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11989305)

  • 1. Increased F-18 fluorodeoxyglucose accumulation in a benign neurofibroma--a pitfall in a patient with thyroid cancer: a case report.
    Gabriel M; Erler H; Donnemiller E; Riccabona G
    Nuklearmedizin; 2002 Apr; 41(2):N14-5. PubMed ID: 11989305
    [No Abstract]   [Full Text] [Related]  

  • 2. FDG PET in thyroid cancer: thyroxine or not?
    Grünwald F; Biersack HJ
    J Nucl Med; 2000 Dec; 41(12):1996-8. PubMed ID: 11138684
    [No Abstract]   [Full Text] [Related]  

  • 3. F-18 FDG PET demonstration of a thyroid metastasis in a patient with colon cancer.
    Iguchi T; Matsuoka J; Sato S; Okumura Y; Omori M; Mifune H; Akaki S; Kanazawa S
    Clin Nucl Med; 2007 May; 32(5):361-2. PubMed ID: 17452862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing paradigms in the follow-up of patients with differentiated thyroid cancer: an alternative to [18F]fluorodeoxyglucose positron emission tomographic scanning.
    Mazzaferri EL
    Endocr Pract; 2003; 9(4):324-6. PubMed ID: 14561580
    [No Abstract]   [Full Text] [Related]  

  • 5. F-18 FDG PET/CT imaging of a subcutaneous scalp metastasis from primary carcinoma of the thyroid.
    Niederkohr RD; Dadras SS; Leavitt M; McDougall IR
    Clin Nucl Med; 2007 Feb; 32(2):162-4. PubMed ID: 17242580
    [No Abstract]   [Full Text] [Related]  

  • 6. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the upper aerodigestive tract].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S67-79. PubMed ID: 12739338
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects.
    Kang KW; Kim SK; Kang HS; Lee ES; Sim JS; Lee IG; Jeong SY; Kim SW
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4100-4. PubMed ID: 12970270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG uptake in benign asymmetric hypertrophy of the masticator muscles.
    Ihn YK; Park YH; Chung SK
    Clin Nucl Med; 2006 Apr; 31(4):221-2. PubMed ID: 16550021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant transformation in an area with elevated F-18 FDG uptake within a low metabolic benign neurofibroma.
    van de Luijtgaarden AC; Flucke UE; van der Graaf WT; de Rooy JW; Bonenkamp HJ; de Geus-Oei LF
    Clin Nucl Med; 2010 Apr; 35(4):271-2. PubMed ID: 20305421
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of thyroid metastases from nasopharyngeal carcinoma with F-18 FDG PET/CT.
    Osmany S; Padhy AK; Ng DC
    Clin Nucl Med; 2008 Mar; 33(3):224-5. PubMed ID: 18287855
    [No Abstract]   [Full Text] [Related]  

  • 11. Fortuitous detection of papillary carcinoma of the thyroid with F-18 FDG positron emission tomography in a patient with non-Hodgkin lymphoma.
    Kim CE; Joyce JM; Patel N; Lichter J
    Clin Nucl Med; 2003 Sep; 28(9):782-3. PubMed ID: 12973010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers.
    Nam SY; Roh JL; Kim JS; Lee JH; Choi SH; Kim SY
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):135-9. PubMed ID: 17465995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [F-18-FDG PET in autonomous goiter].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1999; 38(1):1-6. PubMed ID: 9987775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal pelvic uptake in 18F-FDG PET due to a contraceptive device; a potential pitfall easily unmasked by PET-CT.
    Fuechsel FG; Weidner S; Krause T
    Nuklearmedizin; 2006; 45(4):N42-3. PubMed ID: 16969953
    [No Abstract]   [Full Text] [Related]  

  • 15. How high can the standardized uptake value be?
    Hickeson M; Zhuang H; Chacko TK; Alavi A
    Clin Nucl Med; 2002 Nov; 27(11):819. PubMed ID: 12394139
    [No Abstract]   [Full Text] [Related]  

  • 16. Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation.
    van Tol KM; Jager PL; Piers DA; Pruim J; de Vries EG; Dullaart RP; Links TP
    Thyroid; 2002 May; 12(5):381-7. PubMed ID: 12097198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of FDG PET in differentiated thyroid cancer.
    Macapinlac HA
    J Nucl Med; 2001 Jan; 42(1):77-8. PubMed ID: 11197984
    [No Abstract]   [Full Text] [Related]  

  • 18. [Metabolic imaging of a malignant myxofibrosarcoma with F-18-FDG and C-11-methionine positron emission tomography].
    Weckesser E; Redeker J; Kühnel G; Börner AR; Flügel M; Knapp WH
    Nuklearmedizin; 2000; 39(3):N38-9. PubMed ID: 10834199
    [No Abstract]   [Full Text] [Related]  

  • 19. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the thyroid].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S105-9. PubMed ID: 12739343
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucose metabolism of the thyroid in autonomous goiter measured by F-18-FDG-PE.
    Boerner AR; Voth E; Theissen P; Wienhard K; Wagner R; Schicha H
    Exp Clin Endocrinol Diabetes; 2000; 108(3):191-6. PubMed ID: 10926315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.